Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Finance
US Retinal Therapeutics Market reports more than 15 compounds in phase 2 development or beyond

By 2017, Genentech and Regeneron are expected to split the AMD, DME, and RVO segments with their VEGF inhibitors Lucentis and Eylea


Print article Print article
© companiesandmarkets.com

companiesandmarkets.com
companiesandmarkets.com
2014-03-19 00:33:03 - US Retinal Therapeutics Market reports more than 15 compounds in phase 2 development or beyond - a new market research report on companiesandmarkets.com

The US Retinal Therapeutics Market reports there are more than 15 compounds in Phase 2 development and beyond. If approved, Allergan will have the first once-every-3-months VEGF inhibitor with AGN-150998, expected to launch in 2018 to 2019. If Phase 3 data shows comparable efficacy and safety to current VEGF inhibitors, Allergan has the potential to gain market share due to its less frequent dosing.

Ophthotec´s platelet-derived growth factor (PDGF) inhibitor Fovista has the potential to become the first add-on therapy to VEGF inhibitors. This product has significant market potential due to a complementary rather than competitive add-on therapy strategy. New treatments that can be administered orally or topical drops would revolutionize treatment; however, it appears unlikely that any current pipeline medications

 

 

will have comparable safety and efficacy profiles to current VEGF treatments.

Since the introduction of Lucentis in 2006, vascular endothelial growth factor (VEGF) antagonists have become the clear choice in treatment for age related macular degeneration, diabetic macular edema, and retinal vein occlusion due to their high efficacy and safety.

By 2017, Genentech and Regeneron are expected to split the AMD, DME, and RVO segments with their VEGF inhibitors Lucentis and Eylea, respectively. Eylea´s favorable bi-monthly dosing has enabled Regeneron to be a viable competitor to Genentech´s Lucentis. In 2014, Eylea´s label will expand to include DME.

Eylea and Lucentis are comparably priced; however, Avastin is available through compounding pharmacies at an immense discount, which significantly disrupts the branded AMD, DME, and RVO market. Although new VEGF treatments are highly efficacious, they require intravitreal injections which is an invasive procedure. Thus, dosing frequency is a key determinant of market uptake.

The AMD, DME, and RVO segments are set for continued growth due to an aging US population, and the DME segment in particular due to an increasing prevalence of diabetes.

Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..

About Us
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.com’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.


Author:
Mike King
e-mail
Web: www.companiesandmarkets.com
Phone: London: +44 (0) 203 086 8600

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com